Europe — EMA
Telmisartan + Hidroclorotiazida Ratiopharm (Hydrochlorothiazide, Telmisartan)
Telmisartan + Hidroclorotiazida Ratiopharm combines two active ingredients to support blood pressure management. This fixed-dose oral medication is prescribed f
Request sourcing
What is Hydrochlorothiazide, Telmisartan?
Telmisartan + Hidroclorotiazida Ratiopharm combines two active ingredients to support blood pressure management. This fixed-dose oral medication is prescribed for hypertension in adults. It is designed for convenient once-daily use as directed by a healthcare professional.
What is Hydrochlorothiazide, Telmisartan used for?
This combination medication is used to treat high blood pressure, also known as hypertension. It works by relaxing blood vessels and removing excess fluid to help lower blood pressure. People often ask, 'what is Telmisartan + Hidroclorotiazida used for?' It is prescribed when a single medication is not enough to control blood pressure effectively.
What are the side effects of Hydrochlorothiazide, Telmisartan?
Many users notice improved blood pressure readings within a few weeks of starting this medication. It may help reduce symptoms like headaches or dizziness linked to high blood pressure. Some people experience mild side effects such as dizziness or dry mouth, which are generally temporary.
What precautions apply to Hydrochlorothiazide, Telmisartan?
Take this medication exactly as prescribed by your doctor, usually once daily. It is important to monitor your blood pressure regularly while using this medication. Avoid sudden changes in posture to reduce the risk of dizziness. Stay hydrated and maintain a balanced diet unless advised otherwise.
What does Hydrochlorothiazide, Telmisartan interact with?
This medication may interact with other drugs, including certain pain relievers, potassium supplements, and diuretics. Alcohol use may enhance the blood pressure-lowering effect, leading to dizziness. Always inform your healthcare provider about all medications and supplements you are taking.



